XERS Stock Forecast & Price Target

The positive outlook on Xeris Biopharma Holdings Inc. is supported by significant growth in sales for its products, particularly Recorlev and Gvoke, with Recorlev sales increasing by 131% to $22.6 million in 4Q24 compared to 4Q23, and Gvoke sales rising by 25% to $23.3 million in the same period. Additionally, the company demonstrated strong operating leverage with guidance for operating expenses increasing only in the mid-to-high single digits, suggesting improved efficiency. The substantial growth in new prescriber starts, up approximately 123% in 4Q24 compared to the previous year, signals a broadening market acceptance and potential for continued revenue expansion.

Xeris Biopharma Holdings Inc. reported a 4Q24 net loss per share of ($0.03) on total revenues of $60.1 million, slightly outperforming expectations but still indicating a challenging financial landscape. The company's future revenue guidance for 2025, set at $255-275 million, while above both internal and market estimates, raises concerns about sustainability and growth given existing and potential competition, particularly from new generic entrants. Furthermore, the existence of potential R&D and FDA setbacks adds significant risks, complicating the outlook for the company's financial performance.